BEAM vs CRSP
BEAM and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $2.55B | $5.55B |
| P/B | 2.39 | — |
| P/S | 18.2x | 1579.9x |
| Revenue | $156.03M(TTM) | — |
| Revenue growth (YoY) | 120.0% | -90.6% |
| Net income | -$86.52M(TTM) | — |
| Earnings growth (YoY) | 78.8% | -58.8% |
| EPS, diluted | $-0.69(TTM) | — |
| EBIT margin | -274.6% | -18933.6% |
| ROE | -7.5% | -33.3% |
| ROIC | -40.5% | -32.6% |
| 1y total return | +9.7% | -2.9% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs CRSP
| Metric | BEAM | CRSP |
|---|---|---|
| End value | $13.2K | $10.6K |
| Total return | +31.6% | +5.5% |
| CAGR | +4.2% | +0.8% |
| Volatility | 79.8% | 61.8% |
| Sharpe | 0.39 | 0.25 |
| Sortino | 0.61 | 0.39 |
| Max drawdown | -89.1% | -85.1% |
Based on 1662 common trading days, 2020-02-06 → 2026-09-17 · risk-free 4.12% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)